Guided by Science. Inspired by Life:
Expanding Global Vaccine Access

Substipharm Biologics brings the reliability of European pharmaceutical excellence to the communities that need it most, ensuring proven, high-impact vaccines protect regional health and nurture future generations.

Partner with us

Bridging Innovation and Vaccine Access

For many of the world’s most pressing infectious diseases, the scientific success has already been achieved and highly effective vaccines exist. Yet, a vaccine can only protect lives if it reaches the people who need it. When an individual is protected, the ripple effect strengthens collective immunity — safeguarding families, vulnerable populations, and entire communities. Ensuring access is therefore essential to turning scientific progress into real public health impact.

At Substipharm Biologics, our strategy is shaped entirely around this mission. Operating from Europe, we look past the uncertainty of early-stage discovery to invest directly in execution, scale, and lifecycle care. By acquiring clinically proven vaccines and committing our infrastructure to their sustainable, long-term commercialization, we avoid development risks so we can focus on what matters most: expanding access to reliable prevention for the populations who need it most, from infants and children to entire communities.

Our mission is fundamentally oriented toward preventing diseases. We believe true health stewardship begins by stopping illness before it can start."

Fabrice Baschiera, CEO of Substipharm Biologics

Our Operating Model

European Reliability combined with Biotech Agility

Our model combines the agility of a lean biotech organization with the rigor of European heritage in a single, integrated way of working. It is strengthened by our deep expertise across several areas, including Regulatory Affairs, Quality, Industrial Affairs, and Business Development, while maintaining uncompromising standards in quality control and supply chain resilience.

Focused, Agile Commercialization

Our biotech-driven structure enables fast, informed decision making and targeted execution. We concentrate our resources on bringing clinically proven vaccines to market efficiently, tailoring our commercial strategies to the specific dynamics of each country we serve.

Long‑Term Regional Partnerships

We work closely with health authorities, medical practitioners, pharmaceutical companies, and trusted distribution networks across Asia‑Pacific. By building durable relationships and listening to local needs, we co‑create tailored solutions that strengthen and sustain regional healthcare ecosystems.

Where We Create Impact

We focus on critical therapeutic sectors where vaccine-preventable illnesses continue to disrupt lives, safeguarding both local populations and international travelers against infectious threats, aligning with the global public health priorities of the World Health Organization.

Protecting children’s health

Protecting the early stages of life by ensuring steady, uninterrupted access to essential vaccines that shield infants and young children from severe neurological and infectious complications.

Addressing Endemic & Tropical Threats

Mitigating the heavy burden of vector-borne and regional viral threats like Japanese Encephalitis and Enterovirus 71 by stabilizing regional supply chains so that protection is always within reach.

Strengthening Vaccine Access

Stepping into regional markets where distribution hurdles or supply constraints have historically left vulnerable communities exposed to preventable disease.

Building a Future Ready Vaccine Portfolio

A wide angle view of an adorable playful Japanese child and her mother having fun while sitting in the kitchen.

Our growth strategy focuses on identifying proven vaccines that have not yet reached their full potential. We look for established assets that lack the dedicated attention, scale, or regional presence needed to maximize their impact. By acting as long‑term stewards, we ensure these vaccines continue to grow, evolve, and reach the populations that rely on them.

Expanding Regional Access

We prioritize markets where strong medical need meets limited availability, using our regional infrastructure to bring reliable prevention to underserved communities.

Partnering for Long-Term Value

We collaborate with innovators who seek a committed, compliant partner capable of revitalizing established vaccines and extending their lifecycle.

Ensuring Sustainable Supply

We invest in resilient manufacturing and supply networks to guarantee that each vaccine we steward remains accessible, high quality, and dependable over time.

Partner with us

Japanese Encephalitis (JE)

JE is a leading cause of vaccine-preventable viral encephalitis in Asia. It is a severe infection of the central nervous system caused by the Japanese Encephalitis Virus (JEV), a flavivirus transmitted to humans through the bite of infected Culex mosquitoes. While many infections are asymptomatic, clinical cases are devastating: the disease has a high case-fatality rate of approximately 30%. Among those who survive the acute illness, 30 to 50% suffer from permanent effects of JE: neurological, cognitive, or behavioral sequelae, including paralysis, recurrent seizures, or inability to speak. There is currently no specific antiviral treatment for JE so prevention is key. JE is endemic across 24 countries in the South-East Asia and Western Pacific regions, placing over 3 billion people at risk. Recently, the geographical footprint of the virus has expanded, evidenced by significant outbreaks in previously non-endemic regions like south-eastern Australia.

We provide IMOJEV®, a live attenuated Japanese encephalitis vaccine, in the following countries:

  • Australia
  • Brunei
  • Cambodia
  • Hong Kong
  • Indonesia
  • Malaysia
  • Myanmar
  • New Zealand
  • Philippines
  • Singapore
  • South Korea
  • Thailand​
  • Taiwan
  • Vietnam

Enterovirus 71 (EV71)

EV71 is a primary cause of severe neurological complications, such as encephalitis and meningitis, and associated mortality in young children across the Asia-Pacific region. Recurrent large-scale outbreaks continue to pose significant public health challenges in Southeast Asia. In Vietnam alone, over 100,000 HFMD cases were reported in 2025.

Enterovirus 71 (EV71) is a non-polio enterovirus and a major causative agent of hand, foot, and mouth disease (HFMD), particularly associated with more severe clinical outcomes. It is most prevalent in the Asia-Pacific region, where cyclical outbreaks have been reported for decades, often affecting children under 5 years of age who are the most susceptible due to limited prior immunity. EV71 has notable outbreak potential due to its efficient person-to-person transmission via fecal-oral and respiratory routes, coupled with periodic accumulation of susceptible populations. Given its capacity to cause severe neurologic disease and fatalities in young children, EV71 represents an important public health concern, driving the need for vaccination strategies in endemic countries in addition to standard hygiene measures. ENVACGEN®, an inactivated vaccine against Enterovirus 71 disease, is already available in the following countries:
  • Taiwan
  • Vietnam

Our offices

Bangkok

944 Mitrtown Office Tower
24th Floor, Room S24012
Rama 4 Road, Sub-district Wangmai
Pathumwan District
Bangkok 10330, Thailand

Ho Chi Minh City

Ho Chi Minh City
Regus Worc@Q2 Thao Dien
21 Vo Truong Toan Street, An Khanh Ward, Ho Chi Minh City,
70000 Vietnam

Geneva

Chemin du Pré-Fleuri 1
1228 Plan-Les-Ouates
Geneva, Switzerland